MX2010005046A - Composicion anestesica, formulacion y metodo de uso. - Google Patents

Composicion anestesica, formulacion y metodo de uso.

Info

Publication number
MX2010005046A
MX2010005046A MX2010005046A MX2010005046A MX2010005046A MX 2010005046 A MX2010005046 A MX 2010005046A MX 2010005046 A MX2010005046 A MX 2010005046A MX 2010005046 A MX2010005046 A MX 2010005046A MX 2010005046 A MX2010005046 A MX 2010005046A
Authority
MX
Mexico
Prior art keywords
anesthetic
composition
prepared
component
hyaluronidase
Prior art date
Application number
MX2010005046A
Other languages
English (en)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Publication of MX2010005046A publication Critical patent/MX2010005046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/048—Anaesthetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición anestésica para uso, por ejemplo, en la administración de un anestésico local por inyección comprende un primer componente, que comprende hialuronidasa, y un segundo componente que comprende una preparación anestésica. La composición es tanto efectiva y como altamente estable de caducidad y tiene una ventaja que puede ser almacenada y administrada a temperatura ambiental. En una modalidad particular, la hialuronidasa es preparada en forma de polvo seco, así como por liofilización. El componente anestésico puede ser seleccionado del grupo de anestésicos conocidos, tales como lidocaína, polocaína, xilocaína, novocaína, procaína, prilocaína, bupivacaína, mepivacaína, carbocaína, etidocaína y quinocaína. La composición puede ser preparada en formas de dosificación unitarias, incluyendo una sola forma de dosificación, para una variedad de propósitos, y estas formas de dosificación unitarias pueden ser preparadas enana jeringa con varias cámaras o como dispensador, en donde los componentes no son mezclados hasta la administración.
MX2010005046A 2007-11-06 2008-11-06 Composicion anestesica, formulacion y metodo de uso. MX2010005046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98597607P 2007-11-06 2007-11-06
PCT/US2008/012596 WO2009061482A2 (en) 2007-11-06 2008-11-06 Anesthetic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
MX2010005046A true MX2010005046A (es) 2010-10-15

Family

ID=40532475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005046A MX2010005046A (es) 2007-11-06 2008-11-06 Composicion anestesica, formulacion y metodo de uso.

Country Status (8)

Country Link
US (2) US20090143436A1 (es)
EP (1) EP2214639A2 (es)
JP (1) JP2011517311A (es)
CN (1) CN102159183A (es)
AU (1) AU2008325089A1 (es)
CA (1) CA2704928A1 (es)
MX (1) MX2010005046A (es)
WO (1) WO2009061482A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2304491A1 (en) * 2008-07-10 2011-04-06 Real View Imaging Ltd. Broad viewing angle displays and user interfaces
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US10307467B2 (en) * 2014-07-16 2019-06-04 New York University Use of hyaluronidase for treatment of muscle stiffness
CN105012233B (zh) * 2015-08-24 2018-04-20 段鹏静 一种含有普鲁卡因的用于分娩的组合物及制备方法
WO2017055462A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Multi chamber syringe unit and method of preparing a multi chamber syringe
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
FR3101251B1 (fr) * 2019-09-26 2022-06-24 Sandrine Sebban Formulation pour une application topique sur la peau ou les muqueuses
CN115957332B (zh) * 2022-11-01 2023-10-10 北京华睿鼎信科技有限公司 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226901A (en) * 1988-04-11 1993-07-13 Dhaliwal Avtar S Composite anesthetic article and method of use
WO1994012227A1 (en) * 1992-12-01 1994-06-09 Tetsuro Higashikawa Syringe
US5496284A (en) * 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
JP3982855B2 (ja) * 1995-10-06 2007-09-26 株式会社大協精工 ２室を結合した注射器
EP1762236B1 (en) * 2000-05-12 2015-07-15 Septodont Holding SAS Formulations of alpha adrenergic receptor antagonists and their uses
DE10140704A1 (de) * 2001-08-18 2003-03-06 Vetter & Co Apotheker Verfahren zur Durchmischung einer schwer löslichen pharmazeutischen Substanz mit einem Lösungsmittel und Spritze zur Anwendung des Verfahrens
NZ542873A (en) * 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2006523461A (ja) * 2003-04-15 2006-10-19 イスタ・ファーマスーティカルズ・インコーポレイテッド 羊ヒアルロニダーゼを単離し精製する方法
US8357147B2 (en) * 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
EP1907032A2 (en) * 2005-06-30 2008-04-09 Mallinckrodt, Inc. Dual chamber syringe

Also Published As

Publication number Publication date
JP2011517311A (ja) 2011-06-02
CN102159183A (zh) 2011-08-17
CA2704928A1 (en) 2009-05-14
WO2009061482A2 (en) 2009-05-14
EP2214639A2 (en) 2010-08-11
US20090143436A1 (en) 2009-06-04
WO2009061482A3 (en) 2011-01-13
US20150010528A1 (en) 2015-01-08
AU2008325089A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2010005046A (es) Composicion anestesica, formulacion y metodo de uso.
WO2006033948A3 (en) Sustained local anesthetic composition containing preferably a sugar ester such as saib
ATE244558T1 (de) Trockene formbare arzneistoffformulierung
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
EA201270034A1 (ru) Твердые таблетки лекарства для имплантируемых устройств для доставки лекарств
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
PT2038290E (pt) Moduladores de receptor do tipo toll 7
MY149622A (en) Pyrazoles as 11-beta-hsd-1
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
UA93714C2 (ru) Комбинация активных веществ c инсектицидным действием, применение комбинации kak средства для борьбы c вредителями
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
MY177591A (en) Nk1 receptor antagonist composition
BRPI0614197B8 (pt) composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
AR030957A1 (es) Composiciones de analgesico y glucosamina
WO2006041538A3 (en) A mixture for transdermal delivery of low and high molecular weight compounds
EA200500389A1 (ru) Композиции для ингаляции
TW200628167A (en) Composition for preventing and/or treating metabolic syndrome and insulin resistance syndrome

Legal Events

Date Code Title Description
FA Abandonment or withdrawal